Overview
A Phase 1b/2, open-label, multicenter platform trial to evaluate the antitumor activity and safety of etrumadenant-based combination therapy in participants with metastatic castrate resistant prostate cancer.
Key Eligibility Criteria
- Metastatic castrate-resistant prostate cancer while on anti-androgen treatment with castrate levels of testosterone (≤1.7 nmol/L or 50 ng/dL)
- Naive to any prior treatment with immune checkpoint blockade therapy